Thanks, Chris, and good afternoon, everyone. In the first quarter, as Chris mentioned, we saw continued strong production, actually setting a record for the company for a single quarter's production of approximately $640.4 million for the quarter, which is a 13.7% increase from Q4 last year. We had 1,500 loans funded in the first quarter. That was an increase of almost 18% on the loan count basis over the previous quarter. The strong production growth [in rental volume] included the weighted average coupon and new health investment originations continuing to be strong at 10.5% and the weighted average coupon on our held-for investment originations for the last 5 quarter average trend was at 10.8%. The growth originations in Q1 also continued the tight credit levels with the weighted average loan to value fee just being under 63%, 62.6% and the last 5 quarter average trend at 63.4%. So the strong Q1 production and record growth, a healthy WAC, and low LTV continues to show borrower demand for our products through all different market cycles and environments. If we go to Page 7. As a result of the continued growth in production, page 7 shows the growth in Q1 for our overall loan portfolio at the end of the quarter. Total loan portfolio as of March 31 was just under $5.5 billion in UPB, and that's a 7.8% increase from year-end 2024 and a 27.3% increase year-over-year. Its weighted average coupon portfolio at the end of the quarter was just under 9.6%, at 9.59% which is 6 basis points increase from the WAC at the end of the year and 52 basis points increase from the same time in the first quarter last year. The total portfolio weighted average loan-to-value remained consistently low at 66.1% at the end of the quarter. Going to Page 8. Our Q1 portfolio NIM was 3.35%, representing one of our -- more normalized NIMs compared to Q4 of '24. Q4 of 2024, it was a little bit higher NIM due to cash interest received on non-performing loans. We saw the cash interest on non-performing loans consistently and [indiscernible] lumpy, and that can cause some spikes in the NIM. Our Q1 NIM was consistent on a year-over-year basis. Our portfolio yield for Q1 of this year decreased by 23 basis points quarter-over-quarter, again, due to the high cash nonperforming loan interest received in Q4, but an increase year-over-year by 40 basis loss, while our cost of funds increased by 9 quarter-over-quarter and increased by 30 basis points year-over-year. On Page 9, our nonperforming loan rate at the end of Q1, as Chris mentioned, was 10.8%. That's been relatively flat. It was 10.7% at the end of 2024, and it's been consistent for the last 5 quarters at an average of about 10.5%. We continue to see strong efforts by our special servicing department that resulted in favorable gain resolutions of our NPA assets -- by NPA assets with our NPL loans as well as the REO assets. The table on Page 10 shows the continued positive results of our in-house NPA resolution efforts. Our Q1 NPA resolution gains were $1.9 million or 2.4% of the $76.4 million in overall UPB resolved. And on a trend basis, we've been averaging about a 3.3% quarterly NPL -- NPA resolution gain over the last 5 quarters. Page 11 presents on the left-hand side, our CECL loan loss reserve and on the right-hand side, our net loan charge-off gain loss on REO activity. The CECL reserve at the end of the quarter was $5 million or 22 basis points of our outstanding amortized cost health investment portfolio. The CECL reserve at the end of Q1 was slightly above our expected normal range of 15 to 20 basis points, and that is due to the latest national economic forecast. CECL requires you to do a macroeconomic forecast using a modeling system and the outside model that we use given all the kind of uncertainty and the movement around in Q1 in the markets, it just had a little more severe step on the macroeconomic forecast, it's only 2 basis points, so instead of 20 basis points at year-end, it's 22 basis points. The CECL loan loss reserve number does not include our loans being carried at fair value, just amortized costs. And then in the table to the right of this page shows our net gain loss from both loan charge-offs and REO-related activities during the quarter. And for Q1, the gain on REO activities offset the net loan charge-offs. Page 12 shows our durable funding and liquidity position at the end of the quarter. Total liquidity as of March 31 was $75.6 million that is comprised of $51.7 million in cash and cash equivalents and another $23.9 million in available liquidity on our unfinanced collateral. In addition, the available warehouse line capacity at the end of the quarter was $238 million, with the maximum line capacity of $810 million. As Chris mentioned previously, in Q1, we issued our first securitization of 2025 for $342.8 million in securities issued. And then subsequent to first quarter, in April, we issued our second long-term securitization, 2025-2 and we also issued a short-term securitization, 2025-RTL-1 as the securization of our short-term loans. And remember the very first short-term securitization we ever did was in 2023. So in 2025, we simultaneously collapsed the 2023-RTL-1 short-term securitization and issued the 2025-RTL-1 securitization. And the RTL-1 securitization, I only want to add about that is it includes $59 million in UPB from the old 2023 securitization that was freed up when it was collapsed and it will go to the RTL-1 for 2025. That concludes my first quarter financial recap. I'll turn the presentation back to Chris now for an overview of our '25 outlook.